# Mali Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Mali HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Mali (MLI)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $733.6K
- Products: 13
- Buyer markets: 21
- Average CAGR: +13.5%
- Global sector size: $244.2B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $172.9B | $444.8K | $69.3B | +3.2% | 15 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $14.0B | $26.6K | $7.5B | +112.9% | 4 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.8B | $8.4K | $6.5B | -23.1% | 6 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $10.2B | $56.1K | $6.2B | +14.3% | 5 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $8.5B | $1.3 | $4.3B | -20.7% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $10.2B | $1.1K | $3.9B | +5.8% | 4 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.0B | $39.2K | $2.0B | +18.9% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $3.3B | $6.8 | $1.6B | -3.3% | 2 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $1.6B | $62.0 | $1.2B | +57.0% | 1 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $1.8B | $125.9 | $1.2B | -7.2% | 2 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $669.2M | $598.6 | $1.0B | +0.1% | 1 | +0.0% |
| HS 330290 - Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $113.7 | $803.3M | -6.0% | 1 | +0.0% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $857.1M | $156.4K | $782.6M | +107.8% | 1 | +0.1% |

## Best markets

- Switzerland, Liechtenstein (CHE): $27.7B calculated opportunity across 1 products.
- USA, Puerto Rico and US Virgin Islands (USA): $16.2B calculated opportunity across 6 products.
- Germany (DEU): $9.9B calculated opportunity across 6 products.
- Belgium (BEL): $8.2B calculated opportunity across 2 products.
- Netherlands (NLD): $6.5B calculated opportunity across 3 products.
- France (FRA): $6.5B calculated opportunity across 5 products.
- Canada (CAN): $5.7B calculated opportunity across 3 products.
- China (CHN): $4.6B calculated opportunity across 2 products.
- United Kingdom (GBR): $4.1B calculated opportunity across 1 products.
- Ireland (IRL): $3.2B calculated opportunity across 1 products.
- Poland (POL): $2.1B calculated opportunity across 2 products.
- Taiwan (TWN): $2.0B calculated opportunity across 1 products.

## Growth stars

- HS 382499: +112.9% average CAGR, $7.5B calculated opportunity.
- HS 380893: +107.8% average CAGR, $782.6M calculated opportunity.
- HS 300439: +57.0% average CAGR, $1.2B calculated opportunity.
- HS 381800: +18.9% average CAGR, $2.0B calculated opportunity.
- HS 330300: +14.3% average CAGR, $6.2B calculated opportunity.
- HS 330499: +5.8% average CAGR, $3.9B calculated opportunity.
- HS 300490: +3.2% average CAGR, $69.3B calculated opportunity.
- HS 382319: +0.1% average CAGR, $1.0B calculated opportunity.
- HS 300290: -3.3% average CAGR, $1.6B calculated opportunity.
- HS 330290: -6.0% average CAGR, $803.3M calculated opportunity.

## Diversification opportunities

- HS 300490: 15 buyer markets, $69.3B calculated opportunity.
- HS 382200: 6 buyer markets, $6.5B calculated opportunity.
- HS 330300: 5 buyer markets, $6.2B calculated opportunity.
- HS 382499: 4 buyer markets, $7.5B calculated opportunity.
- HS 330499: 4 buyer markets, $3.9B calculated opportunity.
- HS 300290: 2 buyer markets, $1.6B calculated opportunity.
- HS 330210: 2 buyer markets, $1.2B calculated opportunity.
- HS 300212: 1 buyer markets, $4.3B calculated opportunity.
- HS 381800: 1 buyer markets, $2.0B calculated opportunity.
- HS 300439: 1 buyer markets, $1.2B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.